Urology Practice最新文献_第8页

Effect of Antihistamine on Ureteral Stent-Related Symptoms: A Double-Blind Randomized Controlled Trial. 抗组胺药对输尿管支架相关症状的影响：一项双盲随机对照试验

IF 1.7

Urology Practice Pub Date : 2025-07-01 Epub Date: 2025-02-12 DOI: 10.1097/UPJ.0000000000000791

David S Han, Ezra J Margolin, Miyad Movassaghi, Jeffrey P Johnson, Mahveesh Chowdhury, Srinath-Reddi Pingle, Michael L Schulster, David M Weiner, Ojas Shah

{"title":"Effect of Antihistamine on Ureteral Stent-Related Symptoms: A Double-Blind Randomized Controlled Trial.","authors":"David S Han, Ezra J Margolin, Miyad Movassaghi, Jeffrey P Johnson, Mahveesh Chowdhury, Srinath-Reddi Pingle, Michael L Schulster, David M Weiner, Ojas Shah","doi":"10.1097/UPJ.0000000000000791","DOIUrl":"10.1097/UPJ.0000000000000791","url":null,"abstract":"Introduction: Given evidence of antihistamine's efficacy in bladder pain syndrome and renal colic, we evaluated the effect of antihistamine on ureteral stent-related symptoms.Methods: We performed a double-blind, randomized controlled trial of adults undergoing unilateral ureteroscopy with stent placement for urolithiasis treatment. Coloplast Imajin silicone stents (Coloplast A/S, Humlebaek, Denmark) were used for all procedures. Alongside nonsteroidal anti-inflammatory medications for pain control, patients were randomly prescribed a 10-day course of either fexofenadine 180 mg oral daily (study arm) or placebo (control). The primary outcome was Ureteral Stent Symptoms Questionnaire urinary symptoms and pain scores with stent in situ immediately before stent removal; groups were compared using the Student t test. Higher scores represented increasing symptom severity.Results: Of 73 patients (37 study arm, 36 control arm), mean age was 52 years old, and the majority were male (60%). Mean stone burden (10 mm) and median time to stent removal (9 days) were similar between groups. With stent in situ, there were no differences in urinary symptoms or pain scores between study and control groups (28 vs 29, P = .85 and 14 vs 17, P = .25); moreover, there were no differences between arms in any Ureteral Stent Symptoms Questionnaire domain at this timepoint (P > .05). There were no differences between study and control groups in postdischarge narcotic analgesia use (5% vs 14%, P = .26), total number of office phone calls (5 vs 9, P = .61), or total number of emergency department visits (2 vs 3, P = .67).Conclusions: Postoperative antihistamines were well tolerated but did not significantly reduce ureteral stent-related symptoms.","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"415-425"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

National and Location-Specific Medicare Physician Fee Reimbursement Trends in Urologic Oncology From 2002 to 2024. 2002-2024年泌尿肿瘤国家和地区医疗保险医师费用报销趋势。

IF 1.7

Urology Practice Pub Date : 2025-07-01 Epub Date: 2025-03-05 DOI: 10.1097/UPJ.0000000000000795

Kyle J Kopechek, Matthew Satariano, Tasha Posid, Shawn Dason

{"title":"National and Location-Specific Medicare Physician Fee Reimbursement Trends in Urologic Oncology From 2002 to 2024.","authors":"Kyle J Kopechek, Matthew Satariano, Tasha Posid, Shawn Dason","doi":"10.1097/UPJ.0000000000000795","DOIUrl":"10.1097/UPJ.0000000000000795","url":null,"abstract":"Introduction: In recent years, Medicare physician reimbursement has been a target for national health care spending adjustments, but detailed national and location-specific trends in urologic oncology are lacking. This study investigated reimbursement trends over the past 2 decades.Methods: The Centers for Medicare & Medicaid Services Physician Fee Schedule Look-Up Tool was used to extract physician reimbursement data for urologic oncology procedures from 2002 to 2024. We analyzed 20 common or relevant urologic oncology Current Procedural Terminology codes. Reimbursement data were recorded biennially and inflation adjusted to 2024 US dollars. The compound annual growth rate (CAGR) over the study period was calculated for each procedure. Location-specific reimbursement trends were analyzed for robot-assisted radical prostatectomy (RARP, Current Procedural Terminology 55866) in all available Medicare localities (n = 89).Results: Reimbursement data for the 20 procedures were retrieved with an average inflation-adjusted percentage change of -41.08% from 2002 to 2024. For all procedures, the 2014 to 2024 CAGR indicated a faster rate of decline compared with the 2002 to 2014 CAGR. RARP showed the most significant inflation-adjusted decline. Kidney procedures experienced an average inflation-adjusted CAGR of -2.15%, bladder -2.49%, prostate -2.53%, and testicular -2.34%. Open surgeries averaged a CAGR of -2.32%, endoscopic -2.60%, and laparoscopic/robotic -2.73%. Reimbursement for RARP declined across all 89 Medicare localities from 2014 to 2024, with slight variability in magnitude.Conclusions: Inflation-adjusted Medicare physician reimbursement has been declining for all urologic oncology procedures over the past 2 decades, with more substantial declines noted in recent years. As key stakeholders, urologists must remain active in policy decisions pertaining to physician reimbursement.","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"380-390"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Payments by Drug and Medical Device Manufacturers to Society of Urologic Oncology Fellowship Program Directors. 药品和医疗器械制造商支付给泌尿肿瘤学会（SUO）奖学金项目主任。

IF 1.7

Urology Practice Pub Date : 2025-07-01 Epub Date: 2025-03-18 DOI: 10.1097/UPJ.0000000000000814

David-Dan Nguyen, Anna-Lisa Nguyen, Anju Murayama, Sanchit Kaushal, Rui Bernardino, Marian S Wettstein, Raj Satkunasivam, Quoc-Dien Trinh, Girish S Kulkarni, Deborah C Marshall, Christopher J D Wallis

{"title":"Payments by Drug and Medical Device Manufacturers to Society of Urologic Oncology Fellowship Program Directors.","authors":"David-Dan Nguyen, Anna-Lisa Nguyen, Anju Murayama, Sanchit Kaushal, Rui Bernardino, Marian S Wettstein, Raj Satkunasivam, Quoc-Dien Trinh, Girish S Kulkarni, Deborah C Marshall, Christopher J D Wallis","doi":"10.1097/UPJ.0000000000000814","DOIUrl":"10.1097/UPJ.0000000000000814","url":null,"abstract":"Introduction: This study aims to characterize payments by drug and medical device manufacturers to current program directors (PDs) of the Society of Urologic Oncology (SUO)-accredited fellowship programs in the United States.Methods: PDs were identified from SUO fellowship websites as of February 2024. Demographic data, educational background, and scholarly metrics were collected through an online search. Industry payments to SUO PDs from 2014 to 2023 were extracted from the Open Payments database. Descriptive statistics were used to summarize PD characteristics and industry payment details. Univariable linear regression was used to assess the association of PD characteristics or scholarly metrics with payments.Results: Fifty-one PDs from 37 SUO fellowship programs were identified. PDs were predominantly men (94%) and mid career. In aggregate, over the study period, PDs received US dollars ($) 18,963,555 in industry payments over 10 years. Most payments were for associated research funding ($15,490,525, 81.6%; median [IQR] per PD recipient, $126,584 [$36,565-$706,516]; 1262 payments). General payments accounted for a total of $3,473,030 (18.3%; median [IQR] per PD, $10,345 [$2196-$49,180]). SUO PDs received $120,763 (0.6%) for education fees. No association was found between PD characteristics or research metrics and industry payments.Conclusions: PDs of SUO fellowships receive significant industry payments, surpassing those received by the average urologist. Most of these payments are allocated to research, with smaller proportions directed to general support and educational initiatives.","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"401-407"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143659024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial Commentary. 编辑评论。

IF 1.7

Urology Practice Pub Date : 2025-07-01 Epub Date: 2025-06-23 DOI: 10.1097/UPJ.0000000000000804

Addee Lerner, Jonathan Bergman

引用次数: 0

Editorial Commentary. 编辑评论。

IF 1.7

Urology Practice Pub Date : 2025-07-01 Epub Date: 2025-06-23 DOI: 10.1097/UPJ.0000000000000813

Zachary Werner, Jay Sandlow

引用次数: 0

Reply by Authors. 作者回复。

IF 0.8

Urology Practice Pub Date : 2025-07-01 DOI: 10.1097/UPJ.0000000000000853

Kyle J Kopechek, Shawn Dason

引用次数: 0

Tumors in Solitary Kidneys Are Not All Equal: Outcomes of Partial Nephrectomy in High-Risk Cases. 单肾肿瘤并非都一样：高危病例肾部分切除术的疗效

IF 1.7

Urology Practice Pub Date : 2025-07-01 Epub Date: 2025-03-14 DOI: 10.1097/UPJ.0000000000000802

Mark T Dawidek, Lina Posada Calderon, Juan Sebastian Arroyave Villada, Burcin A Ucpinar, Lennert Eismann, Stephen W Reese, Marc Ganz, Oguz Akin, Ed Reznik, Jonathan A Coleman, A Ari Hakimi, Paul Russo

{"title":"Tumors in Solitary Kidneys Are Not All Equal: Outcomes of Partial Nephrectomy in High-Risk Cases.","authors":"Mark T Dawidek, Lina Posada Calderon, Juan Sebastian Arroyave Villada, Burcin A Ucpinar, Lennert Eismann, Stephen W Reese, Marc Ganz, Oguz Akin, Ed Reznik, Jonathan A Coleman, A Ari Hakimi, Paul Russo","doi":"10.1097/UPJ.0000000000000802","DOIUrl":"10.1097/UPJ.0000000000000802","url":null,"abstract":"Introduction: While partial nephrectomy remains the preferred treatment of tumors in solitary kidneys, there is a broad range of complexity to these cases. This retrospective study refines our understanding of renal and oncologic outcomes in high-risk cases of partial nephrectomy of the solitary kidney (PNSK).Methods: Review of our institutional database identified patients who underwent PNSK between 1990 and 2020. Cases were classified as high-risk PNSK based on having any of the following: clinical stage ≥ T3, RENAL (for radius, exophytic/endophytic, nearness of tumor to collecting system, anterior/posterior, location relative to polar line) nephrometry score ≥ 10, or multiple tumors suspicious for malignancies.Results: Of the 124 cases included, 73 were classified as high-risk PNSK. The rate of high-grade perioperative complications was 32% among high-risk cases, compared with 12% among low-risk cases. The high-risk group recovered less of their baseline renal function compared with the low-risk group, although this gap narrowed with time, and the respective 5-year end-stage renal disease-free survivals were 89% and 100%. Baseline renal function, multifocal tumors, and intraoperative blood loss were predictors of long-term renal function. The 5-year local recurrence-free survival, cancer-specific survival, and overall survival rates in the high-risk group were 83%, 80%, and 77%, respectively.Conclusions: Outcomes of PNSK remain preferrable to end-stage renal disease in the highest-risk patients. Keys to optimization are meticulous preservation of normal parenchyma and a bloodless field. Longer ischemia time is tolerable to achieve these goals, although it may benefit from the application of renal hypothermia.","PeriodicalId":45220,"journal":{"name":"Urology Practice","volume":" ","pages":"441-450"},"PeriodicalIF":1.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial Commentary. 社论评论。

IF 1.7

Urology Practice Pub Date : 2025-07-01 Epub Date: 2025-03-24 DOI: 10.1097/UPJ.0000000000000809

J Stephen Jones

引用次数: 0

Neoadjuvant Chemotherapy and Partial Cystectomy for Muscle-Invasive Bladder Cancer: 20-Year Bladder-Preserved Survival. 肌肉浸润性膀胱癌的新辅助化疗和部分膀胱切除术- 20年膀胱保留生存率。

IF 0.8

Urology Practice Pub Date : 2025-07-01 Epub Date: 2025-03-11 DOI: 10.1097/UPJ.0000000000000807

Harry Herr

引用次数: 0

Reply: Difficulty With Board Certification in Urology Is Associated With Adverse Medical License Actions. 答复：泌尿外科委员会认证困难与不良医疗许可行为有关。